High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays

Abstract We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11), or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of an...

Full description

Saved in:
Bibliographic Details
Published in:Virology (New York, N.Y.) N.Y.), 2010-09, Vol.405 (1), p.31-40
Main Authors: Luevano, Martha, Bernard, Hans-Ulrich, Barrera-Saldaña, Hugo A, Trevino, Victor, Garcia-Carranca, Alejandro, Villa, Luisa L, Monk, Bradley J, Tan, Xiaolin, Davies, D. Huw, Felgner, Phil L, Kalantari, Mina
Format: Article
Language:English
Subjects:
Adenocarcinoma - epidemiology
Adenocarcinoma - immunology
Adenocarcinoma - virology
Adult
Alphapapillomavirus - classification
Alphapapillomavirus - genetics
Alphapapillomavirus - immunology
Antibodies, Viral - blood
Cervical cancer
Child, Preschool
Female
Genome, Viral
High-throughput
Human papillomavirus
Humans
Humoral immuneresponse
Infectious Disease
Microarray
Neoplasms, Squamous Cell - epidemiology
Neoplasms, Squamous Cell - immunology
Neoplasms, Squamous Cell - virology
Papillomavirus
Papillomavirus Infections - epidemiology
Papillomavirus Infections - immunology
Papillomavirus Infections - virology
Protein Array Analysis
Serology
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - immunology
Uterine Cervical Neoplasms - virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11), or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of antibodies in 546 patients, which had either cervical carcinomas, or precursor lesions, or which were asymptomatic. All patient groups contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity. Computational analyses showed the E7 proteins of carcinogenic HPV types as significantly more reactive in cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL patients. Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential reactivity relative to pathology. Our study introduces a new approach to future evaluation of the overall antigenicity of HPV proteins and cross-reaction between homologous proteins.
ISSN:0042-6822
1096-0341
DOI:10.1016/j.virol.2010.05.011